Skip to main content

Health condition

Huntington's disease, a family illness with an increasingly active research field.

A rare inherited disorder of movement, cognition and mood - and one where specialist MDT care, careful genetics and family support make a real difference at every stage.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against NICE, the Huntington’s Disease Association, MHRA and specialist commissioned HD centre standards.

  • 03

    Current for 2026

    Reflects modern UK practice including newer VMAT2 inhibitors and the current status of HTT-lowering trials.

Key facts

Huntington's disease at a glance.

The essentials, in plain English - the genetics, the classic triad, and how HD is cared for in the UK today.

  • What it is

    An autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene on chromosome 4p16.3.

  • Genetics

    More than 39 CAG repeats gives full penetrance, 36 to 39 is reduced penetrance, under 27 is normal. Anticipation is common through paternal inheritance.

  • How common

    Prevalence is roughly 10 in 100,000 in the UK, with many more at risk through family history.

  • Onset

    Typically 30 to 50 years - juvenile Westphal onset under 20 is rare and almost always paternally inherited.

  • The clinical triad

    Movement (chorea, dystonia, bradykinesia, dysarthria), cognitive (executive, memory, dementia) and psychiatric (depression, apathy, irritability, psychosis).

  • Course

    Insidious and progressive over 15 to 20 years. No cure yet - management is specialist, symptomatic and multidisciplinary.

Why this guide matters

A specialist condition with a shared roadmap.

HD is uncommon, inherited and multi-system - which is why care sits in specialist commissioned centres and why families deserve clear, unhurried information.

  • The triad is the compass

    Movement, cognition and mood are all treated in parallel - not one at a time - and reviewed at every clinic visit.

  • Genetics is a family process

    Predictive and cascade testing follow careful UK protocols with counselling built in - never on a same-day basis.

  • Research is genuinely moving

    Newer VMAT2 inhibitors are already licensed, and HTT-lowering therapies remain in active trials in specialist centres.

How the diagnosis is made

From family story to a shared plan.

The steps a UK neurologist and clinical geneticist will normally follow - so you know what to expect and why.

  1. 01

    Assessing

    History and family tree

    A three-generation pedigree looking for chorea, early-onset dementia, psychiatric illness or unexplained suicide - all pointers to autosomal dominant HD.

  2. 02

    Assessing

    Neurological examination

    Structured assessment using the Unified Huntington’s Disease Rating Scale (UHDRS) - motor, cognitive, behavioural and functional domains.

  3. 03

    Assessing

    Psychiatric review

    Depression, anxiety, apathy, irritability, OCD features and suicide risk are screened for at diagnosis and at every review.

  4. 04

    Confirming

    Predictive or diagnostic testing

    HTT gene analysis through NHS specialist clinical genetics - always preceded by pre-test counselling under UK cascade testing protocols.

  5. 05

    Confirming

    MRI brain

    Caudate and putamen atrophy are the classic findings - useful in atypical cases and for tracking disease progression.

  6. 06

    Confirming

    Rule out mimics

    Chorea-acanthocytosis, DRPLA, Wilson’s disease, benign hereditary chorea and drug-induced chorea are considered by the specialist.

  7. 07

    Preparing

    Specialist HD centre referral

    Care sits with specialist commissioned HD centres and the Huntington’s Disease Association - MDT input begins from diagnosis.

Typical timeline: weeks from first neurology visit to genetics review and MDT plan.

Symptoms

What Huntington's actually looks like.

The classic triad of movement, cognitive and psychiatric symptoms - and the features that mean it is time to escalate.

  • Chorea

    Involuntary, flowing, unpredictable movements of the limbs, trunk and face - often the earliest visible motor sign.

  • Dystonia and rigidity

    Sustained abnormal postures and stiffness - more prominent in juvenile-onset and later-stage disease.

  • Bradykinesia and gait

    Slowness of movement, poor balance and falls - a leading cause of injury and hospital admission.

  • Dysarthria and dysphagia

    Slurred speech and swallowing problems - see our guide to dysphagia for detail on assessment.

  • Cognitive change

    Executive dysfunction, slow processing, memory difficulty and eventually dementia.

  • Mood and behaviour

    Depression, apathy, anxiety, irritability, OCD features and psychosis - often the earliest and most disabling symptoms.

  • Juvenile Westphal variant

    Onset under 20 years - rigidity, seizures, cognitive decline and rapid progression. Almost always paternally inherited.

  • Red flag - suicidality

    Suicide risk is significantly increased in HD, particularly around diagnosis and loss of independence. Ask directly, act early.

Treatment

How Huntington's is managed in the UK.

There is no cure yet - but a well-run specialist MDT and modern chorea therapies genuinely improve day-to-day life.

  • Tetrabenazine (Xenazine)

    A VMAT2 inhibitor licensed in the UK for chorea. Effective but needs careful monitoring for depression, parkinsonism and QT changes.

  • Deutetrabenazine (Austedo)

    A deuterated VMAT2 inhibitor with a smoother pharmacokinetic profile - EMA approved in 2023. Prescribed by specialists in HD centres.

  • Valbenazine (Ingrezza)

    Newer VMAT2 inhibitor - EMA approved in 2023 for HD chorea. Once-daily dosing and specialist neurology oversight.

  • Amantadine

    Sometimes used off-label for chorea and rigidity when VMAT2 inhibitors are unsuitable - specialist decision.

  • Botulinum toxin

    Targeted injections for focal dystonia and troublesome oromandibular or cervical involvement.

  • SSRIs and antipsychotics

    For depression, anxiety, irritability and psychosis. Some atypical antipsychotics also help chorea and are prescribed alongside psychiatry input.

  • Speech and swallowing therapy

    Regular specialist SLT input for dysarthria and dysphagia - PEG feeding is discussed in advanced disease.

  • HTT-lowering research

    Antisense oligonucleotide (ASO) and gene therapy trials continue in specialist centres. Tominersen, pridopidine and branaplam programmes were discontinued - the field is active but nothing is yet licensed.

VMAT2-based chorea care is delivered through our VMAT2 inhibitor clinic, focal dystonia through therapeutic botulinum toxin, and cognitive tracking through our memory clinic. Predictive testing sits with specialist commissioned clinical genetics.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, specialist society standards and MHRA safety updates, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your neurologist, clinical geneticist and MDT know your family and history and can tell you which parts apply to you.

  • NICE clinical knowledge summaries and neurology guidance on Huntington’s disease.

  • European Huntington’s Disease Network (EHDN) and specialist commissioned HD centre standards.

  • Huntington’s Disease Association (UK) - patient information and professional guidance.

  • MHRA safety updates on tetrabenazine, deutetrabenazine and valbenazine.

  • UK Genetic Testing Network protocols for predictive and cascade testing in HD.

Red flags

When Huntington's needs urgent attention.

Much of HD care is planned - but these are the situations that need same-day or same-week specialist input.

  • New suicidal thoughts

    Suicide risk peaks around diagnosis and when independence is lost. Any expressed intent needs same-day psychiatric review.

  • Acute psychosis or severe agitation

    Requires urgent assessment by liaison psychiatry - HD centres and community mental health teams coordinate care.

  • Sudden decline or new confusion

    Look for reversible drivers - infection, dehydration, medication changes or unrecognised falls with head injury.

  • Choking or recurrent aspiration

    A dysphagia red flag - urgent SLT review and consideration of texture modification or PEG feeding.

  • Rapid weight loss

    Common in HD from increased energy demand and eating difficulty. Dietitian input and calorie support matter early.

  • Juvenile onset under 20

    The Westphal variant - always specialist paediatric neurology and clinical genetics, almost always paternally inherited.

  • Family member requesting testing

    Predictive testing in HD is specialist commissioned and preceded by dedicated genetic counselling - never a same-day decision.

  • Pregnancy and reproductive planning

    Preimplantation genetic diagnosis, prenatal testing and non-disclosure exclusion testing are all specialist pathways - discuss early.

  • Carer burnout

    The needs of HD families are high. Carer assessment, respite and Huntington’s Disease Association support are part of good care.

Living with it

A long illness, held by a strong team.

Four things that make the biggest difference across the whole HD journey - the team, the family, the plan and the support around them.

A quiet reminder

Small, steady steps carry families a long way.

HD unfolds over years - and the households that do best are usually the ones who lean on their MDT and their HD community early.

  1. 01 Team

    Build the MDT early

    Neurology, psychiatry, SLT, physiotherapy, OT, dietetics, palliative care and the Huntington’s Disease Association all have a role - the earlier they are involved, the smoother the journey.

  2. 02 Family

    Genetics is a family conversation

    Cascade testing, reproductive options and predictive testing all sit within specialist commissioned genetics - and take as much time as the family needs.

  3. 03 Planning

    Advance care planning matters

    Wishes about feeding, ceiling of treatment and end-of-life care are best discussed when communication is still clear - a kindness, not a rushed decision.

  4. 04 Support

    You are not on your own

    The Huntington’s Disease Association, specialist HD advisers and local carer groups make a real difference to how families cope.

Frequently asked

Everything we get asked about Huntington's.

Straight answers on genetics, testing, treatment and where to be seen.

  • What causes Huntington’s disease?

    HD is caused by an expanded CAG trinucleotide repeat in the HTT gene on chromosome 4p16.3. More than 39 repeats gives full penetrance, 36 to 39 is reduced penetrance and under 27 is normal. It is inherited in an autosomal dominant pattern, meaning a child of an affected parent has a 50 per cent chance of inheriting the expansion.

  • What is anticipation and why does it matter?

    Anticipation is the tendency for repeat expansions to grow between generations, especially with paternal transmission - larger expansions mean earlier onset. This is why juvenile Westphal HD is almost always inherited from the father, and why family histories can show apparent worsening across generations.

  • How is Huntington’s diagnosed?

    Diagnosis combines a family history, neurological and psychiatric examination using the UHDRS, and HTT gene analysis through NHS specialist clinical genetics. MRI often shows caudate and putamen atrophy. Genetic testing is always paired with counselling - both for those with symptoms and for at-risk relatives considering predictive testing.

  • Is there a cure?

    Not yet. Care is symptomatic and specialist-led. VMAT2 inhibitors (tetrabenazine, deutetrabenazine, valbenazine) help chorea. Depression, anxiety, apathy and psychosis are treated with SSRIs and antipsychotics. Swallowing, communication, mobility and nutrition are supported by a specialist MDT. Research into HTT-lowering therapies continues in trial settings.

  • Should my relatives be tested?

    Predictive testing in HD is a big decision. It is offered through specialist commissioned clinical genetics with dedicated pre-test and post-test counselling, and never on a same-day basis. Some relatives choose to be tested, others do not - both are valid. Reproductive options including preimplantation genetic diagnosis, prenatal testing and non-disclosure exclusion testing are discussed early where relevant.

  • Where should I be seen?

    Ideally, in a specialist commissioned HD centre with links to the Huntington’s Disease Association and specialist clinical genetics. The MDT typically includes neurology, psychiatry, speech and language therapy, physiotherapy, OT, dietetics, palliative care and social work. Early involvement pays off across the whole illness.

Related content

Keep reading.